AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$17.51
−$0.17 (−0.96%) 4:00 PM ET
After hours$17.51
$0.00 (0.00%) 5:41 AM ET
Prev closePrevC$17.68
OpenOpen$17.40
Day highHigh$17.86
Day lowLow$17.28
VolumeVol986,394
Avg volAvgVol1,510,789
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.24B
P/E ratio
-4.97
EPS
-3.52
Sector
Healthcare
AI report sections
MIXED
MLTX
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics shows short-term price momentum with the stock rebounding from the lower end of its 52-week range and trading above key moving averages, while longer-horizon returns remain deeply negative over 6–12 months. The company’s balance sheet features substantial cash and low liabilities, but operations are loss-making with deteriorating net income and free cash flow. Technical patterns and recent FDA-related news align with a bullish near-term technical backdrop, set against elevated fundamental risk and notable short interest.
MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile
MoonLake Immunotherapeutics has rallied over 30% in the past month following FDA regulatory victories. The company received Fast Track designation for Sonelokimab in treating Palmoplantar Pustulosis and FDA confirmation that existing data is sufficient for approval in Hidradenitis Suppurativa. With $380.5 million in cash runway extending into late 2027, the company has de-risked its investment profile. An upcoming Investor Day on February 23, 2026 will showcase Phase 2 trial data, with potential short squeeze dynamics given 12.7% short interest.
Company has achieved significant de-risking through FDA Fast Track designation and approval pathway confirmation for two disease indications. Strong cash position ($380.5M) eliminates near-term dilution risk. Multiple upcoming catalysts (Investor Day, trial data readouts, BLA submission) provide positive momentum. Short interest of 12.7% creates potential squeeze dynamics. Stock has already rallied 30% in one month on concrete regulatory victories rather than hype.
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
MoonLake Immunotherapeutics announced that the FDA has granted Fast Track designation for sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP), based on positive Phase 2 LEDA trial results. The designation enables more frequent FDA interactions and potential expedited review pathways. The company will discuss this milestone and provide updates on multiple clinical programs at an Investor Day on February 23, 2026, including Phase 2 S-OLARIS data in axial spondyloarthritis and progress toward a BLA submission for hidradenitis suppurativa in H2 2026.
MLTXFDA Fast Track designationsonelokimabpalmoplantar pustulosisPhase 2 LEDA trialhidradenitis suppurativaBLA submissionclinical development
Sentiment note
The company received FDA Fast Track designation for sonelokimab in PPP, which accelerates development and review timelines. This regulatory milestone, combined with positive Phase 2 data and confirmed BLA submission strategy for HS, demonstrates clinical progress across multiple indications and de-risks the development pathway.
NegativeBenzinga• Business Wire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is pursuing a class action lawsuit against MoonLake Immunotherapeutics for allegedly making false and misleading statements about its drug candidate sonelokimab, which led to a significant stock price drop after disappointing Phase 3 trial results.
MLTXsecurities fraudlawsuitdrug trialclass actioninvestor rights
Sentiment note
The company is accused of misleading investors about its drug candidate's effectiveness, resulting in a nearly 90% stock value loss and potential legal action
NegativeBenzinga• Prnewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is pursuing a securities fraud lawsuit against MoonLake Immunotherapeutics, alleging the company made false claims about its drug candidate sonelokimab and misled investors about its treatment superiority, resulting in a 90% stock value loss.
MLTXsecurities fraudlawsuitdrug developmentinvestor claimsstock loss
Sentiment note
Company allegedly made false statements about drug candidate, misled investors, experienced significant stock price collapse after Phase 3 trial results, and is now facing a securities fraud lawsuit
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging securities fraud related to misrepresentations about their drug candidate sonelokimab, which led to significant stock value loss.
Stock lost nearly 90% of its value after Phase 3 trial results revealed alleged misrepresentations about drug efficacy, with lawsuit claiming false statements about drug candidate sonelokimab's performance
NegativeGlobeNewswire Inc.• Rosen Law Firm
MLTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX
Rosen Law Firm is pursuing a securities class action lawsuit against MoonLake Immunotherapeutics, alleging false and misleading statements about their Nanobody technology and its clinical benefits during the period of March 10, 2024 to September 29, 2025.
MLTXsecurities lawsuitclass actionNanobodyinvestor rights
Sentiment note
The lawsuit alleges the company made false statements about its technology's clinical efficacy, suggesting potential misrepresentation of scientific claims and potential investor harm
NegativeGlobeNewswire Inc.• Reed Kathrein
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms
Hagens Berman is pursuing a securities class action lawsuit against MoonLake Immunotherapeutics after its stock plummeted 90% following disappointing Phase 3 trial results for its lead drug sonelokimab, alleging the company made misleading claims about its Nanobody technology's clinical efficacy.
Stock dropped 90% after failed clinical trial, facing lawsuit for allegedly misleading investors about drug efficacy, potential significant financial and reputational damage
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th
A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging misleading investors about its drug candidate sonelokimab, which failed to demonstrate superiority in Phase 3 trials, causing the stock to plummet 89.9%.
MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors – Contact BFA Law before December 15
MoonLake Immunotherapeutics faces a securities fraud class action lawsuit after reporting disappointing Phase 3 VELA trial results for its investigational drug sonelokimab, causing its stock price to drop nearly 90%.
Stock price collapsed by 90% after failed clinical trials, potential regulatory approval challenges, and allegations of misrepresenting clinical data and drug effectiveness
NegativeBenzinga• Business Wire
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Law firm alerts investors about a potential securities fraud class action lawsuit against MoonLake Immunotherapeutics after disappointing Phase 3 drug trial results caused significant stock price decline.
MLTXsecurities fraudlawsuitPhase 3 trialnanobodydrug development
Sentiment note
Stock dropped 89.9% after revealing Phase 3 trial failure for lead drug candidate sonelokimab, with allegations of misleading investors about the drug's potential advantages
NegativeGlobeNewswire Inc.• Holzer & Holzer, Llc
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against MoonLake Immunotherapeutics (MLTX), DexCom, Inc. (DXCM), and Synopsys, Inc. (SNPS)
Law firm Holzer & Holzer reminds investors of upcoming lead plaintiff deadlines for class action lawsuits against MoonLake Immunotherapeutics, DexCom, and Synopsys, alleging false statements and material fact omissions during specific time periods.
Lawsuit alleges false statements about product superiority between March 10, 2024 and September 29, 2025
NegativeGlobeNewswire Inc.• Law Offices Of Howard G. Smith
DEADLINE ALERT for MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Law firm alerts investors about potential securities fraud class action lawsuits for MoonLake Immunotherapeutics, Baxter International, and James Hardie Industries, with upcoming lead plaintiff filing deadlines in December 2025.
Allegations of making false/misleading statements about product efficacy and molecular targets of their therapeutic product
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
